Bydgoszcz

• Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting
  2025-524265-24-00 5 2026-05-21 Dyslipidemia at High to Very High Cardiovascular Risk
• An Open-label Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children with gMG Recruiting
  2025-520993-20-00 4 2026-05-19 Generalized Myasthenia Gravis
• Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS) Recruiting
  2025-524002-16-00 5 2026-05-12 Amyotrophic Lateral Sclerosis
• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043) Recruiting
  2025-524160-38-00 5 2026-05-12 Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorect
• A clinical study of tulisokibart in people with psoriatic arthritis (MK-7240-015) Recruiting
  2025-520997-21-00 4 2026-05-08 Psoriatic arthritis​​
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• Phase 2 Study of REGN13335 in Adult Participants with Pulmonary Arterial Hypertension (PAH) Recruiting
  2024-514754-79-00 4 2026-05-06 Pulmonary Arterial Hypertension (PAH)
• Safety, tolerability, pharmacokinetics, and efficacy of filgotinib for the treatment of polyarticular-course juvenile idiopathic arthritis i … Recruiting
  2024-511593-70-00 5 2026-04-27 Polyarticular-course juvenile idiopathic arthritis
• A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting
  2025-522782-30-00 3 2026-04-07 CCI
• A Long-term Study of Navenibart in Participants with Hereditary Angioedema Recruiting
  2025-521142-22-00 5 2026-03-27 Hereditary Angioedema
• MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth … Recruiting
  2025-522492-28-00 4 2026-03-13 AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis,
• A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting
  2024-513911-28-00 10 2026-03-04 Acute Ischemic Stroke
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting
  2025-523202-32-00 5 2026-02-26 Major Depressive Disorder
• A Phase III, randomized, controlled study of furazidin for bacterial vaginosis. Recruiting
  2024-515332-80-00 5 2026-02-23 Bacterial vaginosis
• A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting
  2025-522702-21-00 4 2026-01-26 Ulcerative Colitis is a type of inflammatory bowel disease, a chronic
• A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting
  2024-520097-36-00 5 2026-01-07 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 10 2025-12-24 Framework for Optimizing, Refining, and Unifying Management of HSCT in
• A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting
  2025-522669-32-00 5 2025-12-18 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
• Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke Recruiting
  2025-522455-26-00 9 2025-12-17 Acute Ischemic Stroke
• A study on the immune response and safety of an investigational chickenpox vaccine and a marketed measles, mumps and rubella vaccine when ad … Recruiting
  2024-518840-18-00 5 2025-12-10 Varicella
• A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma … Recruiting
  2024-512029-10-00 5 2025-12-05 Intermediate risk, non-muscle invasive bladder cancer
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 5 2025-11-13 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
• A study to understand the safety and benefit of AlloNK® with rituximab in patients with hard-to-treat rheumatic diseases Recruiting
  2025-520461-41-00 4 2025-10-22 Systemic Sclerosis (SSc)
• A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting
  2025-520721-21-00 4 2025-10-20 Rheumatoid Arthritis

Showing 49–72 of 707 trials